Feasibility Assessment of the Prophylactic Use of AneuFix at the Time of EVAR Implantation
Feasibility Assessment of the Prophylactic Use of AneuFix at the Time of EVAR Implantation
This study is set up to assess the feasibility and safety of the clinical procedure using AneuFix in a prophylactic setting at the time of EVAR endograft implantation.
The investigational device is called ANEUFIX, which is a product treating the endoleak by blockage of backflowing blood vessels, i.e. by filling the endoleak void and nidus of feeding artery and exit of existing draining arteries.
ANEUFIX is a polymer that cures rapidly (2-4 min at 37°C) after injection into the AAA-sac close to the nidus.
Inclusion Criteria:
Asymptomatic, infrarenal AAA that requires surgery with a high-risk profile of developing endoleak type II in line with the recommendations of Guntner et al:
- Open IMA AND
Infrarenal neck according to the IFU of the EVAR device
Other aortic-iliac anatomical configuration suitable for EVAR according to the criteria of the EVAR device to be used
Patient having a life expectation of at least 2 years
Being older than 18 years
Willing and able to comply with the requirements of this clinical study
Exclusion Criteria:
f.daniels@triple-med.com+31 6 38 19 92 91
t.homsma@triple-med.com+31 6 29 07 80 03